HC Wainwright Analysts Decrease Earnings Estimates for ABEO

Key Points

• HC Wainwright has lowered its earnings estimate for Abeona Therapeutics to ($0.24) per share for Q3 2025, down from a previous estimate of ($0.20), while maintaining a "Buy" rating with a price target of $20.00.
• The consensus estimate for the company's full-year earnings stands at ($1.16) per share, as analysts project a gradual recovery in future quarters.
• Abeona Therapeutics' stock has seen mixed ratings from various analysts, with five rating it as a "Buy," while recent insider trading indicates a significant sell-off of shares by executives.

Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) - Equities researchers at HC Wainwright lowered their Q3 2025 earnings estimates for shares of Abeona Therapeutics in a research note issued on Monday, August 18th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will earn ($0.24) per share for the quarter, down from their prior forecast of ($0.20). HC Wainwright has a "Buy" rating and a $20.00 price objective on the stock. The consensus estimate for Abeona Therapeutics' current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics' Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $1.49 EPS, Q2 2026 earnings at $0.07 EPS, Q3 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.19 EPS and FY2026 earnings at $0.42 EPS.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last issued its earnings results on Thursday, August 14th. The biopharmaceutical company reported $1.71 EPS for the quarter, topping analysts' consensus estimates of ($0.39) by $2.10. The company had revenue of $0.40 million during the quarter, compared to the consensus estimate of $21.71 million.

Other equities research analysts have also recently issued research reports about the stock. Stifel Nicolaus lowered their price target on shares of Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating for the company in a research report on Friday, May 16th. Alliance Global Partners reaffirmed a "buy" rating on shares of Abeona Therapeutics in a research report on Thursday, May 15th. Oppenheimer upped their price target on shares of Abeona Therapeutics from $19.00 to $20.00 and gave the stock an "outperform" rating in a research report on Friday, August 15th. Finally, Wall Street Zen cut shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 15th. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $19.50.

Abeona Therapeutics Stock Up 1.7%

Shares of ABEO traded up $0.12 during mid-day trading on Wednesday, hitting $7.23. The company's stock had a trading volume of 850,820 shares, compared to its average volume of 710,270. The company's 50-day moving average is $6.30 and its 200-day moving average is $5.79. Abeona Therapeutics has a 52-week low of $3.93 and a 52-week high of $7.54. The firm has a market capitalization of $370.75 million, a price-to-earnings ratio of 10.33 and a beta of 1.55. The company has a current ratio of 6.73, a quick ratio of 4.90 and a debt-to-equity ratio of 0.09.

Insider Activity at Abeona Therapeutics

In related news, CEO Vishwas Seshadri sold 69,420 shares of the stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $5.86, for a total transaction of $406,801.20. Following the completion of the sale, the chief executive officer owned 1,234,341 shares of the company's stock, valued at $7,233,238.26. This represents a 5.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Mark Alvino sold 13,093 shares of the stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $5.86, for a total transaction of $76,724.98. Following the sale, the director directly owned 77,252 shares of the company's stock, valued at $452,696.72. The trade was a 14.49% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 231,626 shares of company stock valued at $1,430,587 over the last three months. Company insiders own 6.90% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. acquired a new position in Abeona Therapeutics during the 2nd quarter valued at approximately $25,000. Legal & General Group Plc acquired a new position in Abeona Therapeutics during the 2nd quarter valued at approximately $27,000. Twinbeech Capital LP acquired a new position in Abeona Therapeutics during the 4th quarter valued at approximately $58,000. Riverwater Partners LLC acquired a new position in Abeona Therapeutics during the 2nd quarter valued at approximately $62,000. Finally, Police & Firemen s Retirement System of New Jersey acquired a new position in Abeona Therapeutics during the 2nd quarter valued at approximately $63,000. Institutional investors and hedge funds own 80.56% of the company's stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.